📊 CLOV Key Takeaways
Is Clover Health Investments, Corp.. /de (CLOV) a Good Investment?
Clover Health is a rapidly growing insurance company with strong revenue growth of 40.3% YoY, but this growth masks severe operational deterioration. Despite $1.9B in revenue, the company is hemorrhaging cash with negative operating margins of -4.4%, negative free cash flow of -$69M, and persistent net losses, indicating the business model is fundamentally unprofitable at scale.
Clover Health is growing revenue quickly, but that growth is not yet translating into sustainable profitability, with negative operating margins, negative free cash flow, and net losses still intact. The balance sheet is cleaner than many loss-making peers because it carries no long-term debt and maintains adequate liquidity, but the current cash balance is not especially large relative to ongoing cash burn. Fundamentally, this remains a turnaround story that needs clear evidence of margin expansion and cash flow improvement.
Why Buy Clover Health Investments, Corp.. /de Stock? CLOV Key Strengths
- Strong revenue growth of 40.3% YoY demonstrating market demand and enrollment expansion
- Healthy balance sheet with no long-term debt and $78.3M in cash reducing financial distress risk
- Adequate liquidity with 1.47x current ratio providing short-term operational flexibility
- Meaningful gross profit of $270.9M suggesting some underlying operational capability before fixed costs
- Revenue growth is strong at 40.3% year over year, showing continued top-line momentum
- The company has no long-term debt, which limits financial leverage risk
- Liquidity is still reasonable, with a 1.47x current ratio and positive shareholder equity
CLOV Stock Risks: Clover Health Investments, Corp.. /de Investment Risks
- Persistent operating losses of -$85.5M despite $1.9B in revenue indicate severe unit economics and inability to control operating expenses relative to revenue
- Negative free cash flow of -$69M signals the company is burning cash to fund operations, unsustainable without external funding
- Negative ROE of -27.7% and ROA of -15.8% demonstrate value destruction and extremely poor capital efficiency
- Low gross margin of 14.1% leaves minimal cushion to cover operating expenses, leaving the business vulnerable to any cost structure deterioration
- Negative operating cash flow of -$66.9M indicates cash burn from core operations, not just accounting losses
- Profitability remains weak, with negative operating and net margins despite higher revenue
- Operating cash flow and free cash flow are negative, indicating the business is still consuming cash
- Gross margin of 14.1% leaves limited room for execution mistakes or medical cost pressure
Key Metrics to Watch
- Path to operating profitability and timeline for positive operating margins
- Operating cash flow trajectory and free cash flow burn rate sustainability given current cash reserves
- Cost structure analysis - whether the company can achieve meaningful expense leverage as revenue scales
- Gross margin trends - whether margin expansion is possible or if 14% represents a structural ceiling
- Cash burn rate relative to cash reserves to determine runway before liquidity crisis
- Operating margin improvement and sustained net loss reduction
- Operating cash flow and free cash flow trend relative to the $78.3M cash balance
Clover Health Investments, Corp.. /de (CLOV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Clover Health Investments, Corp.. /de presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CLOV Profit Margin, ROE & Profitability Analysis
CLOV vs Healthcare Sector: How Clover Health Investments, Corp.. /de Compares
How Clover Health Investments, Corp.. /de compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Clover Health Investments, Corp.. /de Stock Overvalued? CLOV Valuation Analysis 2026
Based on fundamental analysis, Clover Health Investments, Corp.. /de has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Clover Health Investments, Corp.. /de Balance Sheet: CLOV Debt, Cash & Liquidity
CLOV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Clover Health Investments, Corp.. /de's revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.42 indicates the company is currently unprofitable.
CLOV Revenue Growth, EPS Growth & YoY Performance
CLOV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $331.0M | -$1.3M | $-0.02 |
| Q2 2025 | $356.3M | -$1.3M | $0.01 |
| Q1 2025 | $346.9M | -$1.3M | $0.00 |
| Q3 2024 | $306.0M | $7.4M | $-0.02 |
| Q2 2024 | $320.1M | $7.4M | $0.01 |
| Q1 2024 | $322.0M | -$19.2M | $-0.05 |
| Q3 2023 | $482.1M | -$28.8M | $-0.09 |
| Q2 2023 | $513.6M | -$28.8M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Clover Health Investments, Corp.. /de Dividends, Buybacks & Capital Allocation
CLOV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Clover Health Investments, Corp.. /de (CIK: 0001801170)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 7, 2026 | 4 | xslF345X06/wk-form4_1775593688.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/wk-form4_1775249965.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/wk-form4_1775248480.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/wk-form4_1775248272.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/wk-form4_1775247922.xml | View → |
❓ Frequently Asked Questions about CLOV
What is the AI rating for CLOV?
Clover Health Investments, Corp.. /de (CLOV) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLOV's key strengths?
Claude: Strong revenue growth of 40.3% YoY demonstrating market demand and enrollment expansion. Healthy balance sheet with no long-term debt and $78.3M in cash reducing financial distress risk. ChatGPT: Revenue growth is strong at 40.3% year over year, showing continued top-line momentum. The company has no long-term debt, which limits financial leverage risk.
What are the risks of investing in CLOV?
Claude: Persistent operating losses of -$85.5M despite $1.9B in revenue indicate severe unit economics and inability to control operating expenses relative to revenue. Negative free cash flow of -$69M signals the company is burning cash to fund operations, unsustainable without external funding. ChatGPT: Profitability remains weak, with negative operating and net margins despite higher revenue. Operating cash flow and free cash flow are negative, indicating the business is still consuming cash.
What is CLOV's revenue and growth?
Clover Health Investments, Corp.. /de reported revenue of $1.9B.
Does CLOV pay dividends?
Clover Health Investments, Corp.. /de does not currently pay dividends.
Where can I find CLOV SEC filings?
Official SEC filings for Clover Health Investments, Corp.. /de (CIK: 0001801170) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLOV's EPS?
Clover Health Investments, Corp.. /de has a diluted EPS of $-0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLOV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Clover Health Investments, Corp.. /de has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLOV stock overvalued or undervalued?
Valuation metrics for CLOV: ROE of -27.7% (sector avg: 15%), net margin of -4.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLOV stock in 2026?
Our dual AI analysis gives Clover Health Investments, Corp.. /de a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLOV's free cash flow?
Clover Health Investments, Corp.. /de's operating cash flow is $-66.9M, with capital expenditures of $2.0M. FCF margin is -3.6%.
How does CLOV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.4% (avg: 12%), ROE -27.7% (avg: 15%), current ratio 1.47 (avg: 2).